These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
275 related articles for article (PubMed ID: 23279938)
61. Fabrication of acyclovir-loaded flexible membrane vesicles (FMVs): evidence of preclinical efficacy of antiviral activity in murine model of cutaneous HSV-1 infection. Sharma G; Thakur K; Setia A; Amarji B; Singh MP; Raza K; Katare OP Drug Deliv Transl Res; 2017 Oct; 7(5):683-694. PubMed ID: 28801835 [TBL] [Abstract][Full Text] [Related]
62. beta-Cyclodextrin-curcumin self-assembly enhances curcumin delivery in prostate cancer cells. Yallapu MM; Jaggi M; Chauhan SC Colloids Surf B Biointerfaces; 2010 Aug; 79(1):113-25. PubMed ID: 20456930 [TBL] [Abstract][Full Text] [Related]
63. Surface functionalization of PLGA nanoparticles by non-covalent insertion of a homo-bifunctional spacer for active targeting in cancer therapy. Thamake SI; Raut SL; Ranjan AP; Gryczynski Z; Vishwanatha JK Nanotechnology; 2011 Jan; 22(3):035101. PubMed ID: 21149963 [TBL] [Abstract][Full Text] [Related]
64. Use of Fourier transform infrared microscopy for the evaluation of drug efficiency. Erukhimovitch V; Talyshinsky M; Souprun Y; Huleihel M J Biomed Opt; 2006; 11(6):064009. PubMed ID: 17212532 [TBL] [Abstract][Full Text] [Related]
65. Enhanced oral paclitaxel bioavailability after administration of paclitaxel-loaded nanosponges. Torne SJ; Ansari KA; Vavia PR; Trotta F; Cavalli R Drug Deliv; 2010 Aug; 17(6):419-25. PubMed ID: 20429848 [TBL] [Abstract][Full Text] [Related]
66. Antiviral activity of esterified alpha-lactalbumin and beta-lactoglobulin against herpes simplex virus type 1. Comparison with the effect of acyclovir and L-polylysines. Sitohy M; Billaudel S; Haertlé T; Chobert JM J Agric Food Chem; 2007 Dec; 55(25):10214-20. PubMed ID: 17990848 [TBL] [Abstract][Full Text] [Related]
68. Effects of cationic liposomes with stearylamine against virus infection. Tahara K; Kobayashi M; Yoshida S; Onodera R; Inoue N; Takeuchi H Int J Pharm; 2018 May; 543(1-2):311-317. PubMed ID: 29625169 [TBL] [Abstract][Full Text] [Related]
69. Enhancement in antifungal activity of eugenol in immunosuppressed rats through lipid nanocarriers. Garg A; Singh S Colloids Surf B Biointerfaces; 2011 Oct; 87(2):280-8. PubMed ID: 21689909 [TBL] [Abstract][Full Text] [Related]
70. Uniform and size-tunable mesoporous silica with fibrous morphology for drug delivery. Gai S; Yang P; Ma P; Wang L; Li C; Zhang M; Jun L Dalton Trans; 2012 Apr; 41(15):4511-6. PubMed ID: 22373780 [TBL] [Abstract][Full Text] [Related]
71. Modulating drug loading and release profile of beta-cyclodextrin polymers by means of cross-linked degree. Wang QF; Li SM; Zhang YY; Zhang H Yao Xue Xue Bao; 2011 Feb; 46(2):221-6. PubMed ID: 21539152 [TBL] [Abstract][Full Text] [Related]
72. Palladium(II) binding to N(7) of acyclovir: DNA interaction and herpes simplex virus (HSV-1) inhibitory activity. Gómez-Segura J; Caballero S; Moreno V; Prieto MJ; Bosch A J Inorg Biochem; 2009 Jan; 103(1):128-34. PubMed ID: 19022504 [TBL] [Abstract][Full Text] [Related]
73. Artesunate-loaded chitosan/lecithin nanoparticles: preparation, characterization, and in vivo studies. Chadha R; Gupta S; Pathak N Drug Dev Ind Pharm; 2012 Dec; 38(12):1538-46. PubMed ID: 22348223 [TBL] [Abstract][Full Text] [Related]
74. Auto-associative heparin nanoassemblies: a biomimetic platform against the heparan sulfate-dependent viruses HSV-1, HSV-2, HPV-16 and RSV. Lembo D; Donalisio M; Laine C; Cagno V; Civra A; Bianchini EP; Zeghbib N; Bouchemal K Eur J Pharm Biopharm; 2014 Sep; 88(1):275-82. PubMed ID: 24835150 [TBL] [Abstract][Full Text] [Related]
75. Central Composite Design for Formulation and Optimization of Solid Lipid Nanoparticles to Enhance Oral Bioavailability of Acyclovir. Hassan H; Adam SK; Alias E; Meor Mohd Affandi MMR; Shamsuddin AF; Basir R Molecules; 2021 Sep; 26(18):. PubMed ID: 34576904 [TBL] [Abstract][Full Text] [Related]
76. Polyethylenimine combined with liposomes and with decreased numbers of primary amine residues strongly enhanced therapeutic antiviral efficiency against herpes simplex virus type 2 in a mouse model. Maitani Y; Ishigaki K; Nakazawa Y; Aragane D; Akimoto T; Iwamizu M; Kai T; Hayashi K J Control Release; 2013 Mar; 166(2):139-46. PubMed ID: 23298614 [TBL] [Abstract][Full Text] [Related]
77. Improving oral bioavailability of acyclovir using nanoparticulates of thiolated xyloglucan. Madgulkar A; Bhalekar MR; Dikpati AA Int J Biol Macromol; 2016 Aug; 89():689-99. PubMed ID: 27026342 [TBL] [Abstract][Full Text] [Related]
78. Synergistic in vitro interactions between (22S,23S)-3beta-bromo-5alpha,22,23-trihydroxystigmastan-6-one and acyclovir or foscarnet against herpes simplex virus type 1. Talarico LB; Castilla V; Ramirez JA; Galagovsky LR; Wachsman MB Chemotherapy; 2006; 52(1):38-42. PubMed ID: 16340198 [TBL] [Abstract][Full Text] [Related]
79. Optimisation of multiple W/O/W nanoemulsions for dermal delivery of aciclovir. Schwarz JC; Klang V; Karall S; Mahrhauser D; Resch GP; Valenta C Int J Pharm; 2012 Oct; 435(1):69-75. PubMed ID: 22154877 [TBL] [Abstract][Full Text] [Related]
80. Effect of Acyclovir Solid Lipid Nanoparticles for the Treatment of Herpes Simplex Virus (HSV) Infection in an Animal Model of HSV-1 Infection. Kondel R; Shafiq N; Kaur IP; Singh MP; Pandey AK; Ratho RK; Malhotra S Pharm Nanotechnol; 2019; 7(5):389-403. PubMed ID: 31465287 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]